BAYN (BAYN) News
Track canonical SquawkNews coverage tagged to BAYN, BAYN. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 39 indexed stories across 19 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Bayer agrees to sell Stivarga rights to Gruenenthal for up to $431M
Bayer will sell rights to its cancer drug Stivarga to Gruenenthal Group for up to 375 million euros ($430.7 million), with patent protection in the EU expiring in 2029 and in the U.S. a year later, the acquirer said.
MNA | Sep 21, 2026, 12:09 PM UTC
M
Bayer announces Series A financing to advance engineered biologicals
Bayer said it is announcing a Series A financing round to advance engineered biologicals.
EQUITY | Sep 17, 2026, 01:11 PM UTC
M
FDA approves Bayer’s Kerendia for chronic kidney disease in type 1 diabetes
Bayer said the FDA approved Kerendia (finerenone) to treat adult patients with chronic kidney disease associated with type 1 diabetes, its third approved indication in the U.S.
REGULATION | Sep 17, 2026, 07:21 AM UTC
M
FDA approves Bayer’s KERENDIA (finerenone) for CKD with type 1 diabetes
Bayer said the FDA approved KERENDIA (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR) in adults with chronic kidney disease (CKD) and type 1 diabetes, with the therapy expected to reduce the risk of sust
REGULATION | Sep 17, 2026, 06:39 AM UTC
M
Apollo closes €3 billion capital solution for Bayer; KKR joins
Apollo-managed funds closed a previously announced €3 billion capital solution for Bayer. KKR joins as a minority participant.
EQUITY | Sep 16, 2026, 07:01 AM UTC
L
Weekly Recap: Sevabertinib FDA approval and BAY 3670549 Ph II trial
Bayer AG (XETR:BAYN) is advancing oncology, cardiology and sustainability: sevabertinib won FDA accelerated first—line approval for HER2—mutant NSCLC after strong Phase 1/2 results, a Phase II GIRK4 inhibitor trial for a
REGULATION | Sep 14, 2026, 05:15 AM UTC
L
Voyageur Pharmaceuticals secures $1 million on first Bayer milestone
Voyageur Pharmaceuticals Ltd. said it achieved its first milestone under a non-dilutive Bayer collaboration, securing a $1 million payment.
EQUITY | Sep 10, 2026, 01:30 PM UTC
H
FDA grants accelerated approval for Bayer HYRNUO sevabertinib in HER2-mutated NSCLC
Bayer said the U.S. Food and Drug Administration granted accelerated approval for HYRNUO (sevabertinib) for first-line treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung canc
EQUITY | Sep 10, 2026, 02:21 AM UTC
M
Bayer receives FDA accelerated approval for HER2-mutant lung cancer drug
Bayer received FDA accelerated approval for sevabertinib as a first-line treatment for advanced HER2-mutant non-small cell lung cancer patients, after priority review and breakthrough therapy status.
REGULATION | Sep 09, 2026, 06:55 PM UTC
L
Bayer and Neste plan to expand renewable fuel feedstock
Bayer and Neste aim to expand feedstock for renewable diesel and sustainable aviation fuel.
EQUITY | Sep 09, 2026, 12:05 PM UTC
L
Bayer and Neste enter commercial agreement
Bayer and Neste entered a commercial agreement.
EQUITY | Sep 09, 2026, 12:04 PM UTC
L
Bayer, Neste to Jointly Scale Winter Canola for Biofuels Production
Bayer, Neste to Jointly Scale Winter Canola for Biofuels Production
EQUITY | Sep 09, 2026, 12:02 PM UTC
L
Bayer and Neste close commercial agreement on Newgold® winter canola
Bayer AG and Neste have closed a commercial agreement to jointly scale Newgold® winter canola for biofuels production.
EQUITY | Sep 09, 2026, 12:01 PM UTC
L
Bayer closes commercial agreement with Neste
Bayer AG has closed a commercial agreement with Neste.
EQUITY | Sep 09, 2026, 12:01 PM UTC
M
Bayer starts Phase II study of atrial fibrillation drug candidate
Bayer has started a Phase II study of an atrial fibrillation drug candidate.
EQUITY | Sep 09, 2026, 06:34 AM UTC
M
Bayer targets €3bn+ peak with soy traits and 2029 margin
Bayer is launching commercial soy traits targeting >€3bn peak sales and expanding R&D, digital tools and biologicals to reach above-market growth and ~25% EBITDA margin by 2029, while managing Climara supply shortfall to
EQUITY | Sep 07, 2026, 05:15 AM UTC
H
Corn and Soybean Prices Are Popping. How to Play It. — Barrons.com
By Andrew BaryCommodities have rallied this year and agricultural products have joined the party in the past month.That could translate into higher food prices and overall inflation, complicating the job of the Federal R
MACRO | Sep 04, 2026, 04:55 PM UTC
L
J.P. Morgan says Bayer ag unit’s 2029 potential is underrated
J.P. Morgan analysts said the market may not fully grasp Bayer’s agricultural unit potential. In a Wednesday event, the German conglomerate reiterated its 2029 forecast for the business.
EQUITY | Sep 03, 2026, 09:56 AM UTC
L
BAYN update cites margin expansion, cash productivity and innovation growth
A comprehensive update says progress on its Five-Year Framework remains strong, with margin expansion, cash productivity and innovation-driven growth on track. Corn is cited as the main growth engine.
EQUITY | Sep 02, 2026, 11:54 PM UTC
L
BAYN reaffirms above-market growth and mid-20s EBITDA margin target for 2029
BAYN reaffirmed above-market growth and a mid-20s EBITDA margin target by 2029, citing innovation, operational efficiency and differentiated platform strategies, supported by R&D, digital integration and cost savings.
EARNINGS | Sep 02, 2026, 07:24 PM UTC
L
Bayer targets mid-20% EBITDA margin and above-market growth by 2029
Bayer says it is targeting above-market growth and a mid-20% CEBITDA margin by 2029, citing progress in margin, sales and cash flow initiatives.
EQUITY | Sep 02, 2026, 01:34 PM UTC
L
Bayer growth targets supported by new crop science launches
Bayer is launching multiple blockbuster crop science products, with two already commercialized and more planned, targeting over €3 billion in peak sales from new soy traits. AI-driven R&D and genome editing are accelerat
EARNINGS | Sep 02, 2026, 01:23 PM UTC
L
Trump administration to announce drug pricing deals
TradingView News reports the Trump administration will announce drug pricing deals.
EQUITY | Aug 31, 2026, 04:07 PM UTC
L
Weekly Recap: Eighth Circuit upholds Roundup and Kerendia Japan filing
Weekly Recap: Eighth Circuit upholds Roundup and Kerendia Japan filing
EQUITY | Aug 31, 2026, 05:14 AM UTC
L
Bayer to present Phase III REVEAL Iodine-124 Evuzamitide PET study
Bayer announced its Phase III REVEAL study using investigational PET radiotracer Iodine 124 Evuzamitide, presented as a late-breaker at ESC 2026.
EQUITY | Aug 30, 2026, 11:45 AM UTC
L
Bayer Roundup plan survives another court detour
Bayer’s $7.25 billion Roundup plan has survived another court detour, per TradingView News.
EQUITY | Aug 28, 2026, 06:06 PM UTC
L
ESC guidelines give Class IA recommendation for finerenone in heart failure
ESC guidelines provide a Class IA recommendation for finerenone for heart failure.
EQUITY | Aug 28, 2026, 02:07 PM UTC
L
Bayer files in Japan for expanded Kerendia use
Bayer has filed in Japan for expanded use of Kerendia.
EQUITY | Aug 28, 2026, 06:34 AM UTC
M
U.S. court dismisses appeal over $7.25B Roundup deal objections
A U.S. court dismissed an appeal tied to objections to a $7.25 billion Roundup deal.
EQUITY | Aug 27, 2026, 08:25 PM UTC
M
DAX opens 0.15% higher as Infineon leads gains
The DAX Index is up 40 points, or 0.15%, on Friday, with Infineon, Adidas and RWE among the leading gainers and Qiagen, MTU Aero Engines and Bayer among the biggest losers.
EQUITY | Aug 21, 2026, 07:31 AM UTC
L
Bayer Court Hearing Rescheduled
Bayer court hearing rescheduled to Sept 14
REGULATION | Aug 06, 2026, 06:10 PM UTC
M
Bayer Reschedules Class Settlement Hearing
Bayer reschedules settlement hearing to September 10th
EQUITY | Aug 05, 2026, 04:53 PM UTC
H
Bayer Target Price Raised To EUR 61
JP Morgan raises target price
EQUITY | Aug 05, 2026, 05:45 AM UTC
L
Bayer Pursues Settlement
Bayer says Monsanto to still pursue class settlement final approval
EQUITY | Jun 25, 2026, 02:18 PM UTC
M
Bayer Reviews SCOTUS Ruling
Bayer is reviewing the SCOTUS ruling which should result in dismissal of current warning-based claims and bar future failure-to-warn claims
REGULATION | Jun 25, 2026, 02:05 PM UTC
H
Bayer Wins SCOTUS Ruling
The US Supreme Court rules in favor of Bayer's bid to limit lawsuits in state court claiming Roundup weedkiller causes cancer
REGULATION | Jun 25, 2026, 02:01 PM UTC
M
Bayer, Lilly Criticize Germany
Eli Lilly and Bayer are criticizing Germany's spending on new medicines
EQUITY | Jun 23, 2026, 05:40 PM UTC
M
Bayer, Lilly Criticize Germany
Bayer and Eli Lilly criticize Germany's spending on new medicines
EQUITY | Jun 23, 2026, 05:30 PM UTC